Combining Therapies May Boost Long-Term Smoking Cessation Success

For many, breaking free from nicotine addiction is a formidable challenge, often requiring a multi-faceted approach. A recent systematic review and meta-analysis aimed to shed light on whether combining two established smoking cessation aids—varenicline and nicotine replacement therapy (NRT)—could offer a more effective pathway to long-term abstinence than using either treatment alone. Researchers meticulously analyzed data from seven trials involving 2631 participants, following rigorous PRISMA guidelines to assess the primary outcome of smoking abstinence at follow-up periods of six months or longer.

The key discovery was that combination therapy was associated with statistically significantly higher abstinence rates when compared to varenicline used on its own. Participants receiving both treatments showed statistically significantly higher abstinence rates compared with varenicline alone. However, when combination therapy was compared to NRT alone, the effect on abstinence was not statistically significant, largely due to the limited number of studies available for this specific comparison.

While the combination showed promise in efficacy, the analysis also revealed an increase in adverse events (AEs) with the dual approach compared to varenicline alone. Specifically, skin reactions were notably more common, particularly when NRT patches were used alongside varenicline. Despite this, serious adverse events (SAEs) were infrequent and generally deemed unrelated to the treatment regimens, indicating that the combination therapy is, for the most part, well-tolerated by patients.

In conclusion, the gathered evidence, albeit of low certainty, suggests a potential benefit of combining varenicline with nicotine replacement therapy to achieve better long-term smoking cessation rates than varenicline alone. As lead author Zhou notes in the paper, "Low-certainty evidence indicates that combining varenicline with nicotine replacement therapy may improve long-term smoking cessation rates compared with varenicline alone and is generally well tolerated." This approach presents a valuable strategy for clinicians and individuals seeking to overcome nicotine addiction, balancing increased effectiveness with a manageable profile of adverse events.